8-K: Cidara Therapeutics Acquired by Merck for $221.50/Share

Cidara Therapeutics, Inc. has completed its merger with Merck Sharp & Dohme LLC, becoming a wholly-owned subsidiary.

Summary

• Cidara Therapeutics, Inc. completed its merger with Merck Sharp & Dohme LLC (Parent) and Caymus Purchaser, Inc. (Purchaser) on January 7, 2026.
• The acquisition was executed through a tender offer, where Common Shares were acquired for $221.50 per share in cash and Series A Convertible Voting Preferred Stock for $15,505.00 per share in cash.
• The tender offer expired on January 6, 2026, at one minute following 11:59 p.m., Eastern Time.
• A total of 27,149,333 Common Shares and 89,956 Series A Shares were validly tendered and not withdrawn, representing approximately 88.3% of total voting shares outstanding (on an as-converted basis for Series A Shares).
• An additional 1,384,630 Common Shares, representing approximately 3.66% of issued and outstanding shares, were tendered via guaranteed delivery procedures.
• Following the tender offer, Purchaser merged into Cidara Therapeutics, Inc., with Cidara becoming a wholly-owned subsidiary of Parent.
• All outstanding equity incentive plans, including the 2015, 2020, and 2024 Equity Incentive Plans and the 2015 Employee Stock Purchase Plan, were terminated.
• Outstanding options, restricted stock units (RSUs), and warrants were converted into cash payments based on the merger consideration.
• Cidara's Common Shares were delisted from The Nasdaq Stock Market LLC effective before the opening of trading on January 7, 2026.
• The company intends to file a Form 15 with the SEC to terminate registration and suspend its reporting obligations under the Exchange Act.

Sentiment

Score: 8

Explanation: The filing confirms the successful completion of a previously announced acquisition, providing a clear exit for shareholders at a predetermined price. This is a positive and expected outcome for the company and its investors.

Positives

• Shareholders received a cash payment for their shares, providing liquidity and a defined return on their investment.
• The acquisition price of $221.50 per Common Share and $15,505.00 per Series A Share represents a specific and final valuation for the company's equity.
• Cidara's therapeutic assets and pipeline now benefit from the resources and backing of a major pharmaceutical company, Merck.

Negatives

• Cidara Therapeutics, Inc. ceases to be an independent publicly traded company, removing its stock from public markets.
• Existing equity incentive plans were terminated, converting to cash, which alters the long-term incentive structure for employees.
• Shareholders no longer participate in any potential future growth or appreciation of Cidara as an independent entity.

Risks

• Stockholders who properly exercised and perfected their statutory rights of appraisal under the DGCL may pursue legal action, which could result in additional costs for the acquirer.

Future Outlook

Cidara Therapeutics, Inc. is now a wholly-owned subsidiary of Merck Sharp & Dohme LLC. Its public reporting obligations will cease, and its future operations will be integrated into the Parent company's structure and strategic objectives.

Management Comments

• The company terminated its 2015 Equity Incentive Plan, 2020 Inducement Incentive Plan, 2024 Equity Incentive Plan, and 2015 Employee Stock Purchase Plan in connection with the merger.
• The company notified Nasdaq of the merger's consummation and requested the halt of trading and delisting of Common Shares effective before the opening of trading on January 7, 2026.
• The company intends to file a Form 15 with the SEC to terminate the registration of Common Shares and suspend its reporting obligations under the Exchange Act as promptly as practicable.

Industry Context

This acquisition reflects a continuing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, innovative firms to expand their pipelines and market share. Merck's acquisition of Cidara likely aims to integrate Cidara's therapeutic assets into its own portfolio, strengthening its position in specific disease areas.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash for their shares, concluding their investment in the public entity.
• Employees: Equity incentive plans were terminated and converted to cash; a new management team was appointed, which may lead to organizational and operational changes.
• Customers and Suppliers: No direct impact mentioned, but integration into Merck's operations may alter future business relationships.
• Creditors: The company's financial backing is now provided by Merck, potentially strengthening its financial stability.

Next Steps

• Nasdaq will file a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Common Shares.
• The company intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC to terminate registration and suspend its reporting obligations.

Key Dates

Keywords

Cidara Therapeutics, Merck, acquisition, merger, tender offer, common stock, preferred stock, delisting, Nasdaq, pharmaceutical, biotechnology, corporate governance, equity plans